4.760USD+6.01%Mkt Cap: 235.64M USDP/E: —Last update: 2026-05-26
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) p…
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap235.64M USD
Enterprise Value40.26M USD
Revenue (TTM)7.14M USD
Gross Profit6.38M USD
Net Income (TTM)-20.60M USD
Revenue/Share0.1150 USD
Last Price4.760 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees23
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.21
PEG—
EV/EBITDA-0.35
EV/Revenue5.63
P/S29.76
P/B1.49
EPS (TTM)-2.49
EPS (Forward)-1.34
52W Range
1.57081% of range5.495
52W High5.495 USD
52W Low1.570 USD
Profitability
Gross Margin89.36%
Oper. Margin-1601.12%
EBITDA Margin0.00%
Profit Margin-288.26%
ROE-15.11%
ROA-13.66%
Growth
Revenue Growth-100.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-97.43M USD
CapEx (TTM)552.00K USD
FCF Margin-750.92%
FCF Yield-22.77%
Net Debt-145.70M USD
Net Debt/EBITDA1.27
Balance Sheet
Debt/Equity0.00
Current Ratio10.26
Quick Ratio10.04
Book Value/Sh2.891 USD
Cash/Share3.087 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateAug 27, 2021
Analyst Consensus
Rating2.2 (Buy)
Target (Mean)6.500 USD
Target Range4.000 USD – 8.000 USD
# Analysts4
Ownership
Shares Out.49.45M
Float18.15M
Insiders13.75%
Institutions72.47%
Short Interest
Short Ratio4.0d
Short % Float2.20%
Short % Out.1.65%
Shares Short780.06K
Short (prev mo.)722.19K
Technical
SMA 503.918 (+21.5%)
SMA 2002.766 (+72.1%)
Beta0.71
S&P 52W Chg28.31%
Avg Vol (30d)406.02K
Avg Vol (10d)709.28K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—